Literature DB >> 21558079

Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).

Wolfgang Wick, Michael Weller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558079      PMCID: PMC3093341          DOI: 10.1093/neuonc/nor046

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  14 in total

1.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

Review 2.  The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.

Authors:  M Weller; A Fontana
Journal:  Brain Res Brain Res Rev       Date:  1995-09

Review 3.  Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.

Authors:  Wolfgang Wick; Ulrike Naumann; Michael Weller
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

4.  SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.

Authors:  Martin Uhl; Steffen Aulwurm; Jörg Wischhusen; Markus Weiler; Jing Ying Ma; Ramona Almirez; Ruban Mangadu; Yu-Wang Liu; Michael Platten; Ulrich Herrlinger; Alison Murphy; Darren H Wong; Wolfgang Wick; Linda S Higgins; Michael Weller
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2.

Authors:  W Wick; C Grimmel; C Wild-Bode; M Platten; M Arpin; M Weller
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

6.  RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

Authors:  Manuel A Friese; Jörg Wischhusen; Wolfgang Wick; Markus Weiler; Günter Eisele; Alexander Steinle; Michael Weller
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

7.  The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.

Authors:  P Jachimczak; U Bogdahn; J Schneider; C Behl; J Meixensberger; R Apfel; R Dörries; K H Schlingensiepen; W Brysch
Journal:  J Neurosurg       Date:  1993-06       Impact factor: 5.115

8.  Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

Authors:  Thomas-Toan Tran; Martin Uhl; Jing Ying Ma; Lisa Janssen; Venkataraman Sriram; Steffen Aulwurm; Irene Kerr; Andrew Lam; Heather K Webb; Ann M Kapoun; Darin E Kizer; Glenn McEnroe; Barry Hart; Jonathan Axon; Alison Murphy; Sarvajit Chakravarty; Sundeep Dugar; Andrew A Protter; Linda S Higgins; Wolfgang Wick; Michael Weller; Darren H Wong
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

9.  Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.

Authors:  Nicholas J Laping; Jeffrey I Everitt; Kendall S Frazier; Mark Burgert; Melisa J Portis; Caprice Cadacio; Leslie I Gold; Cheryl L Walker
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

10.  Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.

Authors:  U Bogdahn; P Hau; G Stockhammer; N K Venkataramana; A K Mahapatra; A Suri; A Balasubramaniam; S Nair; V Oliushine; V Parfenov; I Poverennova; M Zaaroor; P Jachimczak; S Ludwig; S Schmaus; H Heinrichs; K-H Schlingensiepen
Journal:  Neuro Oncol       Date:  2010-10-27       Impact factor: 12.300

View more
  7 in total

Review 1.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

Review 2.  Targeting TGF-β Signaling for Therapeutic Gain.

Authors:  Rosemary J Akhurst
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-10-03       Impact factor: 10.005

Review 3.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

4.  Transforming growth factor-β pathway activity in glioblastoma.

Authors:  Karl Frei; Dorothee Gramatzki; Isabel Tritschler; Judith Johanna Schroeder; Larisa Espinoza; Elisabeth Jane Rushing; Michael Weller
Journal:  Oncotarget       Date:  2015-03-20

5.  Target mRNA inhibition by oligonucleotide drugs in man.

Authors:  Helen L Lightfoot; Jonathan Hall
Journal:  Nucleic Acids Res       Date:  2012-09-18       Impact factor: 16.971

Review 6.  Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.

Authors:  Powell Perng; Michael Lim
Journal:  Front Oncol       Date:  2015-07-06       Impact factor: 6.244

7.  Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors.

Authors:  Laurent-Olivier Roy; Marie-Belle Poirier; David Fortin
Journal:  Int J Mol Sci       Date:  2018-04-08       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.